Danna Breen, Ph.D.

Research Fellow at Pfizer

Speaker

Danna M. Breen joined Pfizer in 2012 and is currently a Research Fellow for the Internal Medicine Research Unit at Pfizer located in Cambridge, MA. In this role Dr. Breen has led numerous research teams to advance projects in the pipeline in multiple disease areas including cachexia and obesity, and has played a key role in the development of the anti-GDF15 antibody Ponsegromab that is currently in clinical development for cancer cachexia and heart failure.

Prior to joining Pfizer, Dr. Breen completed her graduate training at the University of Toronto where she focused on basic research in fundamental mechanisms in metabolic regulation. Dr. Breen has published numerous refereed papers in the world’s leading scientific journals, including Cell Metabolism, PNAS and Nature Medicine.

In 2022 Dr. Breen received the Breakthrough Science and Innovation Prize in recognition of her remarkable scientific leadership in the research in GDF15 and cancer cachexia, which is the Pfizer Worldwide Research and Development’s highest honor.